Francesco Granata, M.D. Joins Board of Prismic Pharmaceuticals

USA - English

• USA - español
• USA - Italiano
• USA - Deutsch
• USA - Français

SCOTTSDALE, Ariz., Dec. 3, 2013 /PRNewswire/ -- Prismic Pharmaceuticals, Inc., a Scottsdale, Arizona-based, commercial-stage pharmaceutical company focused on prescription Medical Foods, today announced the election of Francesco Granata, M.D., to its Board of Directors.

Dr. Granata is currently Executive in Residence at Warburg Pincus, a leading private equity firm focused on growth investing.  He is an accomplished healthcare executive with more than 35 years of experience in the international pharmaceutical and biotechnology industries.  Before joining Warburg Pincus, Dr. Granata held senior management positions at Pfizer, where he was President of the Northern Europe region; Schering-Plough, where he served as Group Vice President and President for the Europe and Canada region; and most recently at Biogen Idec Inc., where he was Executive Vice President of Global Commercial Operations, with responsibility for worldwide Commercial Operations and Medical Affairs.  Dr. Granata is also a Board Member of Circassia, a UK-based specialty Biopharmaceutical company and Italfarmaco, one of Italy's leading international pharmaceutical groups. 

"Francesco Granata has had an exceptionally successful career and brings a wealth of healthcare experience and strategic vision to our Board of Directors," commented Peter Moriarty, Chairman and CEO of Prismic.  "Prior to joining the pharmaceutical industry, Francesco practiced as a physician and surgeon, specializing in Cardiology.  He has also been Chairman of the European Committee of the Pharmaceutical Research and Manufacturers Association of America and Co-Chairman of the Heads of Europe Committee of the European Federation of Pharmaceutical Industries and Associations.  We are honored that he has accepted the invitation to join our Board.  We are confident of the contribution he will make in helping the Board to guide Prismic's continuing path to commercial success and increased value for our shareholders."  

"Prismic has an extremely interesting and innovative portfolio of patent-protected products," stated Dr. Granata. "I believe that the company has identified products and market opportunities that are medically important as well as commercially very attractive. Prismic has the choice of exploiting those opportunities alone or in partnership with other commercial entities in the United States and Internationally.  I look forward to working with my fellow Board members to help Management drive optimum value for our shareholders."

About Prismic Pharmaceuticals, Inc.
Prismic Pharmaceuticals, Inc., is a privately held, commercial-stage pharmaceutical company focused on the development and marketing of prescription Medical Foods for the clinical dietary management of the metabolic processes associated with many of the disorders associated with the aging population, particularly where inflammation is involved.  The company, founded in 2011, is headquartered in Scottsdale, Arizona, with offices in Boston, USA, and London, England. Contact 480.422.1810 or visit www.PrismicPharma.com.

INFORMATION CONTACT
Peter Moriarty
Tel: 480.422.1810

SOURCE Prismic Pharmaceuticals, Inc.